Optimising antiemetic therapy: what are the problems and how can they be overcome?

References

• Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines [American Society of Clinical Oncology]. J Clin Oncol 1999;17:2971–94
   PubMed Web of Science ®Google Scholar
• SHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729–64
   PubMed Web of Science ®Google Scholar
• Kris MG, Hesketh PJ, Herrstedt J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Supportive Care Cancer 2005;13(2):85–96
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network©. NCCN clinical practice guidelines in oncology™: antiemesis. Version 1. 2004. www.nccn.org
   Google Scholar
• Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. Supportive Care Cancer 2002;10:519–22
   PubMed Web of Science ®Google Scholar
• Rittenberg CN. A new class of antiemetic agents on the horizon. Clin J Oncol Nurs 2002;6:103–4
   PubMedGoogle Scholar
• Bender CM, McDaniel RW, Murphy-Ende K, et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 2002;6:94–102
   PubMedGoogle Scholar
• Feyer PC, Stewart AL, Titlbach OJ. Aetiology and prevention of emesis induced by radiotherapy. Supportive Care Cancer 1998;6:253–60
   PubMedGoogle Scholar
• Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992;77: 162–84
   Google Scholar
• Doherty KM. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 1999;3:113–9
   PubMedGoogle Scholar
• Ritter Jr HL, Gralla RJ, Hall SW, et al. Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Cancer Invest 1998; 16:87–93
   PubMed Web of Science ®Google Scholar
• Laszlo J. Emesis as limiting toxicity in cancer chemotherapy. In: Laszlo J, editor. Antiemetics and cancer therapy. Baltimore/ London: Williams & Wilkins; 1983. p. 1–5
   Google Scholar
• Henriksson R, Lomberg H, Israelsson G, Zackrisson B, Franzen L. The effect of ondansetron on radiation-induced emesis and diarrhoea. Acta Oncol 1992;31:767–9
   Google Scholar
• Lindley C, Blower P. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health-Syst Pharm 2000;57:1685–97
   PubMed Web of Science ®Google Scholar
• Andrews PLR, Davis CJ. The mechanism of emesis induced by anti-cancer agent therapies. In: Andrews PLR, Sanger GJ, editors. Emesis in anti-cancer therapy. London: Chapman and Hall; 1993. p. 113–61
   Google Scholar
• DeVane CL. Substance P: a new era, a new role. Pharmacotherapy 2001;21:1061–9
   PubMed Web of Science ®Google Scholar
• Grelot L, Dapzol J, Esteve E, et al. Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist. Br J Pharmacol 1998;124:1643–50
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Kawasaki Y, Mikami M, et al. Relationship between cancer chemotherapeutic drug-induced delayed emesis and plasma levels of substance P in two patients with small cell lung cancer. Gan To Kagaku Ryoho 1999;26:535–8
   PubMedGoogle Scholar
• Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000;18:163–73
   PubMed Web of Science ®Google Scholar
• Yalcin S, Tekuzman G, Baltali E, Ozisik Y, Barista I. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study. Am J Clin Oncol 1999;22:94–6
   Google Scholar
• Constenla M. 5-HT3 receptor antagonists for prevention of late acute-onset emesis. Ann Pharmacother 2004;38(10):1683–91
   PubMed Web of Science ®Google Scholar
• Martin M. The severity and pattern of emesis following different cytotoxic agents. Oncology 1996;53(Suppl 1):26–31
   PubMedGoogle Scholar
• Feyer P. Nausea und emesis in der Strahlentherapie. Im Focus Onkologie 2002;8:64–8
   Google Scholar
• Aapro M. Methodological issues in antiemetic studies. Invest New Drugs 1993;11:243–53
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103–9
   PubMed Web of Science ®Google Scholar
• Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 1991;14:238–42
   PubMed Web of Science ®Google Scholar
• Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 1992;340:96–9
   PubMed Web of Science ®Google Scholar
• Roila F. Ondansetron plus dexamethasone compared to the ‘standard’ metoclopramide combination. Oncology 1993;50:163–7
   PubMed Web of Science ®Google Scholar
• Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 2003;14:291–7
   Google Scholar
• Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 2003;8:187–98
   PubMed Web of Science ®Google Scholar
• Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995;29:95–109
   PubMed Web of Science ®Google Scholar
• Carmichael J, Cantwell BM, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989;24:45–9
   PubMed Web of Science ®Google Scholar
• Anzemet® (dolasetron mesylate). Aventis Pharmaceuticals Inc., Kansas City, MO, USA; 2000: Prescribing Information
   Google Scholar
• Navoban® (tropisetron hydrochloride). Novartis New Zealand Ltd, Avondale, Auckland, New Zealand; 2001: Prescribing Information
   Google Scholar
• Piraccini G, Stoltz R, Tei M, et al. Pharmacokinetic features of a novel 5-HT3-receptor antagonist: palonosetron (RS-25259–197). Proc Am Soc Clin Oncol 2001 [abstract 1595]
   Google Scholar
• Kytril® tablets (granisetron hydrochloride) Prescribing Information. Nutley NJ, Roche Laboratories Inc 2000
   Google Scholar
• Zofran® (ondansetron hydrochloride). North Chicago, IL, USA, Glaxo Wellcome 2000: Prescribing Information
   Google Scholar
• Piraccini G, Gallagher SC, Macchiocchi A, et al. Palonosetron: a phase II dose ranging study to assess, over a 7-day period, the single-dose pharmacokinetic profile of palonosetron in patients receiving highly emetogenic chemotherapy. Proc Am Soc Clin Oncol 2002;21 [abstract 449]
   Google Scholar
• Newberry NR, Watkins CJ, Sprosen TS, Blackburn TP, Grahame-Smith DG, Leslie RA. BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology 1993;32: 729–35
   Google Scholar
• Eisenberg P, MacKintosh F, Ritch P, Cornett P, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 2004;15:330–7
   Google Scholar
• Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570–7
   Google Scholar
• Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473–82
   PubMed Web of Science ®Google Scholar
• Cohen L, de Moor C, Eisenberg P, et al. Delayed chemotherapy-induced nausea and vomiting remains a problem and significantly interferes with daily function in patients receiving emetogenic chemotherapy in the United States. Proc Am Soc Clin Oncol 2003;22:739 [abstract 2972]
   Google Scholar
• Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003;39:1074–80
   PubMed Web of Science ®Google Scholar
• Navari R, Madajewicz S, Anderson N, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995;13:2408–16
   PubMed Web of Science ®Google Scholar
• Tanihata S, Oda S, Kakuta S, Uchiyama T. Antiemetic effect of a tachykinin NK1 receptor antagonist GR205171 on cisplatin-induced early and delayed emesis in the pigeon. Eur J Pharmacol 2003;461:197–206
   PubMed Web of Science ®Google Scholar
• Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759–67
   PubMed Web of Science ®Google Scholar
• Van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002;94:3032–41
   PubMed Web of Science ®Google Scholar
• Warr D, Gralla R, Hesketh P, et al. The oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: 2 randomized, double-blind, placebo controlled trials. Proc Am Soc Clin Oncol 2003;22:726 [abstract 2919]
   Google Scholar
• de Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403–10
   PubMed Web of Science ®Google Scholar
• Warr DG, Eisenberg P, Hesketh PJ, et al. Phase III, double-blind study to assess an aprepitant-containing regimen for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy. Proc Am Soc Clin Oncol 2004; [late-breaking abstract 8007]
   Google Scholar
• Sanchez LA, Holdsworth M, Bartel SB. Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications. Pharmacoeconomics 2000;18: 533–56
   Google Scholar
• Bubalo J, Seelig F, Karbowicz S, Maziarz RT. Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7:439–45
   PubMed Web of Science ®Google Scholar
• Grote TH, Pineda LF, Figlin RA, et al. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy [Oral Dolasetron Dose Response Study Group]. Cancer J Sci Am 1997;3:45–51
   PubMed Web of Science ®Google Scholar
• Mantovani G, Maccio A, Bianchi A, et al. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 1996;77:941–8
   PubMed Web of Science ®Google Scholar
• Marty M, Kleisbauer JP, Fournel P, et al. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? [The French Navoban Study Group]. Anticancer Drugs 1995;6(Suppl 1):15–21
   PubMedGoogle Scholar
• Chua DT, Sham JS, Kwong DL, et al. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study. Am J Clin Oncol 2000;23:185–91
   PubMed Web of Science ®Google Scholar
• Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study [The Ondansetron and Granisetron Emesis Study Group]. Oncology 1994;51:113–8
   PubMed Web of Science ®Google Scholar
• Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995; 6:805–10
   PubMed Web of Science ®Google Scholar
• Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992;10:1969–75
   PubMed Web of Science ®Google Scholar
• Jantunen IT, Muhonen TT, Kataja VV, Flander MK, Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy – a randomised study. Eur J Cancer 1993;29A:1669–72
   Google Scholar
• Dempsey CL, Coop AJ, Shillington A, et al. Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. Am J Health-Syst Pharm 2004;61:781–6
   PubMed Web of Science ®Google Scholar
• Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of five 5-HT3-receptor antagonists (5-HT3-RAs) for acute chemotherapy-induced emesis. Proc Am Soc Clin Oncol 2004;23:737 [abstract 8048]
   Google Scholar
• Abenhardt W, Hitz H, Völkl S, et al. Comparison of ondansetron 8mg (OND8) vs. granisetron 1 mg (GRA1) vs. granisetron 3 mg (GRA3) in the daily oncological practice. Supportive Care Cancer 2004;12:370 [abstract A–16]
   Google Scholar
• Italian Group for Antiemetic Research. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004;22:725–9
   PubMed Web of Science ®Google Scholar
• Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998;16:2937–42
   PubMed Web of Science ®Google Scholar
• Goldsmith B. Antiemetic patterns of care for radiotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 2003;22:740 [abstract 2975]
   Google Scholar
• Feyer P, Seegenschmiedt MH. Antiemetic patterns of care for radiotherapy-induced nausea and vomiting. Presented at the European Congress of Clinical Oncologists Annual Meeting, 2003. Abstract 929
   Google Scholar
• Goodin S, Cunningham R. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist 2002;7:424–36
   PubMed Web of Science ®Google Scholar
• Wood M. Pharmacokinetic drug interactions in anaesthetic practice. Clin Pharmacokinet 1991;21:285–307
   PubMed Web of Science ®Google Scholar
• Davis MP, Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Supportive Care Cancer 2001;9:442–51
   PubMed Web of Science ®Google Scholar
• May FE, Stewart RB, Cluff LE. Drug interactions and multiple drug administration. Clin Pharmacol Ther 1977;22:322–8
   Google Scholar
• Karas Jr S. The potential for drug interactions. Ann Emerg Med 1981;10:627–30
   PubMed Web of Science ®Google Scholar
• Riechelmann RP, Smaletz Ó, Saad ED. Drug interactions in cancer inpatients. Proc Am Soc Clin Oncol 2004 [abstract 8146]
   Google Scholar
• Tucker GT. Advances in understanding drug metabolism and its contribution to variability in patient response. Ther Drug Monit 2000;22:110–3
   PubMed Web of Science ®Google Scholar
• Dixon CM, Colthup PV, Serabjit-Singh CJ, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995;23: 1225–30
   Google Scholar
• Firkusny L, Kroemer HK, Eichelbaum M. In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron. Biochem Pharmacol 1995;49: 1777–84
   Google Scholar
• Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 1996;24: 602–9
   Google Scholar
• Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 1994;38:557–66
   PubMed Web of Science ®Google Scholar
• Aloxi™ (palonosetron HCL injection) Prescribing Information. Cardinal Health, Albuquerque, NM, USA. Helsinn Birex Pharmaceuticals, Dublin, Ireland. Distributed by MGI Pharma Inc, Bloomington, MN, USA. July 2003
   Google Scholar
• Herrstedt J. The development of a new 5-HT3 receptor antagonist: from pharmacology to clinics. Presented at the Multinational Association for Supportive Care in Cancer meeting, 18–21 June 2003, Berlin, Germany
   Google Scholar
• Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ, Jones RB. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999;24:1–4
   PubMed Web of Science ®Google Scholar
• Gilbert CJ, Petros WP, Vredenburgh J, et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 1998;42:497–503
   PubMed Web of Science ®Google Scholar
• Koriech OM. Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients. Clin Oncol (R Coll Radiol) 1995;7:371–2
   PubMedGoogle Scholar
• Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol 1999;13:313–7
   PubMed Web of Science ®Google Scholar
• De Witte JL, Schoenmaekers B, Sessler DI, Deloof T. The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Anesth Analg 2001;92:1319–21
   PubMed Web of Science ®Google Scholar
• Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-Hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002;20:2805–11
   PubMed Web of Science ®Google Scholar
• Emend® Merck & Co., Inc., Whitehouse Station, New Jersey, 2003. Prescribing information
   Google Scholar
• Aprepitant FDA Advisory Committee Background Package, March 6, 2003. BG1037.doc Version 3.0 approved, January 31, 2003. Available from: www.fda.gov/ohrms/dockets/ac/03/ briefing/3928B1_01_Merck%20Backgrounder.pdf [accessed 21 June 2004)]
   Google Scholar
• Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290–300
   PubMed Web of Science ®Google Scholar
• Blum RA, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25:1407–19
   PubMed Web of Science ®Google Scholar
• Blower PR. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J 2002;8:405–14
   PubMed Web of Science ®Google Scholar
• Gridelli C, Rossi A, Maione P. Polypharmacy in the elderly cancer patient – is there a risk? Presented at the 7th International Society of Geriatric Oncology Annual Meeting, 27–28 September 2002, Boston, MA, USA
   Google Scholar
• Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362–72
   PubMed Web of Science ®Google Scholar
• Keefe DL. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? Oncologist 2002;7:65–72
   PubMed Web of Science ®Google Scholar
• Lowenthal RM, Eaton K. Toxicity of chemotherapy. Hematol Oncol Clin North Am 1996;10:967–90
   PubMed Web of Science ®Google Scholar
• Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003;45:55–75
   PubMed Web of Science ®Google Scholar
• Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991;83: 1888–94
   Google Scholar
• Hunt TL, Cramer M, Shah A, Stewart W, Benedict CR, Hahne WF. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 1995;35:705–12
   PubMed Web of Science ®Google Scholar
• Benedict CR, Arbogast R, Martin L, Patton L, Morrill B, Hahne W. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996;28:53–9
   PubMed Web of Science ®Google Scholar
• Goodin S, Cunningham R. In reply: evidence for equivalent cardiotoxicity of the 5-HT3-receptor antagonists. Oncologist 2003;8:219–21
   Web of Science ®Google Scholar
• Boike SC, Ilson B, Zariffa N, Jorkasky DK. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health-Syst Pharm 1997;54:1172–6
   Google Scholar
• Upward JW, Arnold BD, Link C, Pierce DM, Allen A, Tasker TC. The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur J Cancer 1990;26(Suppl 1): S12–5
   PubMed Web of Science ®Google Scholar
• Carmichael J, Harris AL. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemother Pharmacol 2004;53:123–8
   PubMed Web of Science ®Google Scholar
• Carmichael J, Harris AL. High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability. Anticancer Drugs 2003;14:739–44
   Google Scholar
• Aapro M, Bourke JP. Rapid intravenous administration of granisetron prior to chemotherapy is not arrythmogenic: results of a pilot study. Eur J Cancer 2003;39:927–31
   PubMed Web of Science ®Google Scholar
• Ashkanani F, Heys SD, Eremin O. The management of cancer in the elderly. J R Coll Surg Edinburgh 1999;44:2–10
   PubMedGoogle Scholar
• Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80:1273–83
   PubMed Web of Science ®Google Scholar
• Aapro M. 5-HT3 receptor antagonists and cardiovascular safety, an obvious issue in the elderly. Presented at the 7th International Society of Geriatric Oncology Annual Meeting, 27–28 September 2002, Boston, MA, USA
   Google Scholar
• Orr WC, Chen CL. Aging and neural control of the GI tract: IV. Clinical and physiological aspects of gastrointestinal motility and aging. Am J Physiol Gastrointest Liver Physiol 2002;283: G1226–31
   Web of Science ®Google Scholar
• Schroder J, Kratz B, Pantel J, Minnemann E, Lehr U, Sauer H. Prevalence of mild cognitive impairment in an elderly community sample. J Neural Transm Suppl 1998;54:51–9
   PubMedGoogle Scholar
• Yee KW, Pater JL, Pho L, Zee B, Siu LL. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 2003;21:1618–23
   Google Scholar
• Aapro MS. How do we manage patients with refractory or breakthrough emesis? Supportive Care Cancer 2002; 10:106–9
   PubMed Web of Science ®Google Scholar
• Terrey J-P, Aapro MS. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res 1996;8:281–8
   Google Scholar
• Carmichael J, Keizer HJ, Cupissol D, Milliez J, Scheidel P, Schindler AE. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs 1998;9:381–5
   PubMed Web of Science ®Google Scholar
• de Wit R, de Boer AC, vd Linden GH, Stoter G, Sparreboom A, Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 2001;85:1099–101
   PubMed Web of Science ®Google Scholar
• de Wit R. Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. Br J Cancer 2003;88:1823–7
   PubMed Web of Science ®Google Scholar
• Blower P, Aapro M. Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade? Br J Cancer 2002;86: 1662–3
   PubMed Web of Science ®Google Scholar